title: Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis.
abstract: The aim of this study was to determine whether pretreatment status of human epidermal growth factor receptor-2 (HER-2) could predict pathologic response to neoadjuvant chemoradiotherapy (nCRT) and outcomes for patients with locally advanced rectal cancer (LARC). A total of 119 patients diagnosed with LARC received standardized multimodal treatment. Their HER-2 status was determined in pretreatment biopsies by immunohistochemistry (IHC) and FISH. Tumor response was assessed in resected regimens using the tumor regression grade system and TNM staging system. Twenty-two cases in 119 patients assessed as IHC3+ or IHC2+ plus gene-amplified were determined as HER-2 positive. Positive HER-2 status was not associated with any pretreatment clinicopathologic parameters (P > 0.05). HER-2 status could not predict pathologic response to nCRT based on downstaging (P = 0.210) and tumor regression grade (P = 0.085) but it provides us with a trend that HER-2-positive tumors may be resistant to nCRT. Positive HER-2 status was significantly associated with poor 5-year disease-free survival (P = 0.015) and 5-year overall survival (P = 0.026). It can act as a worse prognostic factor for LARC patients.
authors.affiliation: Medical School of Shandong University, Jinan, China; Department of Radiation Oncology of Shandong Cancer Hospital and Institute, Jinan, China.
authors.forename: Xiangjiao
authors.initials: X
authors.lastname: Meng
authors.forename: Renben
authors.initials: R
authors.lastname: Wang
authors.forename: Zhaoqin
authors.initials: Z
authors.lastname: Huang
authors.forename: Jianbo
authors.initials: J
authors.lastname: Zhang
authors.forename: Rui
authors.initials: R
authors.lastname: Feng
authors.forename: Xiaoqing
authors.initials: X
authors.lastname: Xu
authors.forename: Kunli
authors.initials: K
authors.lastname: Zhu
authors.forename: Xue
authors.initials: X
authors.lastname: Dou
authors.forename: Dong
authors.initials: D
authors.lastname: Chen
authors.forename: Jinming
authors.initials: J
authors.lastname: Yu
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011237:Predictive Value of Tests; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D012004:Rectal Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: HER-2; neoadjuvant chemoradiotherapy; rectal cancer; survival; tumor response
references.citation: Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1460-5
references.pmid: 12459370
references.citation: Int J Colorectal Dis. 2011 Sep;26(9):1127-34
references.pmid: 21538055
references.citation: Br J Cancer. 2013 Feb 19;108(3):668-75
references.pmid: 23348520
references.citation: Mod Pathol. 2001 Jun;14(6):556-62
references.pmid: 11406656
references.citation: Radiother Oncol. 2005 Feb;74(2):93-100
references.pmid: 15816106
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Clin Oncol. 2009 Nov 1;27(31):5124-30
references.pmid: 19770376
references.citation: Lancet Oncol. 2012 Jul;13(7):679-87
references.pmid: 22627104
references.citation: Cancer. 2010 Nov 15;116(22):5336-9
references.pmid: 20665503
references.citation: Cell Oncol (Dordr). 2013 Jul;36(4):311-21
references.pmid: 23722824
references.citation: J Clin Oncol. 2010 Apr 1;28(10):1638-44
references.pmid: 20194850
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8688-96
references.pmid: 16246976
references.citation: Oncology. 1998 Nov-Dec;55(6):548-55
references.pmid: 9778622
references.citation: J Clin Oncol. 2011 Jul 10;29(20):2773-80
references.pmid: 21606427
references.citation: Int J Colorectal Dis. 1997;12(1):19-23
references.pmid: 9112145
references.citation: J Surg Oncol. 2008 Jan 1;97(1):8-13
references.pmid: 18085619
references.citation: J Surg Oncol. 2011 Oct;104(5):458-65
references.pmid: 21557226
references.citation: Lancet. 2010 Aug 28;376(9742):687-97
references.pmid: 20728210
references.citation: Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):195-200
references.pmid: 16839708
references.citation: N Engl J Med. 2004 Oct 21;351(17):1731-40
references.pmid: 15496622
references.citation: Am J Surg Pathol. 2013 Apr;37(4):522-31
references.pmid: 23282976
references.citation: Nature. 1984 Dec 6-12;312(5994):513-6
references.pmid: 6095109
references.citation: Strahlenther Onkol. 2011 Apr;187(4):225-30
references.pmid: 21424305
references.citation: J Cell Physiol. 2004 Sep;200(3):343-50
references.pmid: 15254961
references.citation: Clin Cancer Res. 2012 Jan 15;18(2):546-54
references.pmid: 22252257
references.citation: Adv Anat Pathol. 2011 Jan;18(1):53-9
references.pmid: 21169738
references.citation: Ann Oncol. 2001;12 Suppl 1:S3-8
references.pmid: 11521719
references.citation: Histol Histopathol. 2013 Jun;28(6):787-94
references.pmid: 23255089
references.citation: Int J Colorectal Dis. 2007 May;22(5):491-7
references.pmid: 16947041
references.citation: Science. 1985 Dec 6;230(4730):1132-9
references.pmid: 2999974
references.citation: Mod Pathol. 2012 May;25(5):637-50
references.pmid: 22222640
references.citation: Lancet Oncol. 2011 Jun;12(6):575-82
references.pmid: 21596621
references.citation: Diagn Mol Pathol. 2001 Sep;10(3):139-52
references.pmid: 11552716
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153